The cell therapy processing market was valued at $1,695 million in 2018, and is projected to reach $12,062 million by 2026, registering a CAGR of 27.8% from 2019 to 2026.
Cell therapy processing refers to administration of living cells in a patient’s body for treating a disease. For cell processing therapy, different types of cells can be utilized, including neural cells, skeletal muscle cells, embryonic stem cells, hematopoietic stem cells, and mesenchymal cells. Moreover, it is used for the treatment of cancers, repairmen of spinal cord injuries, infectious & urinary diseases, autoimmune diseases, improvement of a weakened immune system, rebuilding damaged cartilage in joints, and helping patients with neurological disorders.
Increase in the demand for chimeric antigen receptor (CAR) T cell therapy, rise in the R&D for the advancement in the research associated with cell therapy, rise in the incidence of cardiovascular diseases, rise in the potential of cell therapies in the treatment of diseases associated with lungs using stem cell therapies, and increase in a number of clinical studies relating to the development of cell therapy processing are the major factors that drive the growth of the cell therapy processing market. In addition, introduction of novel technologies for cell therapy processing, large number of oncology-oriented cell-based therapy clinical trials, increase in adoption of regenerative drug, rise in government investments for cell-based research, and increase in number of GMP-certified production facilities across the globe are further expected to propel the growth of the cell therapy processing market. However, high-costs associated with the cell therapies, and bottlenecks experienced by manufacturers during commercialization of cell therapies are expected to hinder the growth of the market. Furthermore, the emerging economies present lucrative opportunities for the market.
Cell Therapy Processing Market Segmentation
The cell therapy processing market is segmented into offering type, application, and region. By type, the market is categorized into products, services, and software. The application covered in the segment include cardiovascular devices, bone repair, neurological disorders, skeletal muscle repair, cancer, and others. On the basis of region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, and rest of Asia-Pacific), and LAMEA (Latin America, Middle East, and Africa).
Segment review
Based on offering type, the market is categorized into products, services, and software. At present, products segment dominates the cell therapy processing market, and is anticipated to continue this trend over the forecast period. The key factors that driving the market growth are rise in the incidence of cardiovascular diseases, increase in demand for cell therapy processing, surge in adoption of allogeneic cell therapy, and introduction of novel technologies for cell therapy processing are majorly driving the growth of this segment. Some of the major market players that offer cell therapy processing products are BioTime, Inc., Regeneus Ltd., Targazyme, Inc., Bone Therapeutics, NeuroGeneration, and Invitrx Therapeutics, Inc.
By Product
Products is projected as one of the most lucrative segment.
Based on application, the market is classified into cardiovascular devices, bone repair, neurological disorders, skeletal muscle repair, cancer, and others. The skeletal muscle repair is the major shareholder in the global cell therapy processing market owing to rise in incidence of skeletal muscle injury, rise in geriatric population, increase in prevalence of chronic diseases, increase in usage of regenerative medicine, and increase in adoption of minimally invasive surgeries.
By Application
Skeletal muscle repair holds a dominant position in 2018 and would continue to maintain the lead over the forecast period.
Snapshot of Asia-Pacific cell therapy processing market
Asia-Pacific presents lucrative opportunities for the key players operating in the cell therapy processing market, due to increase in patient awareness toward benefits offered by cell therapy processing, rise in number of hospitals equipped with advanced medical facilities, development of the R&D sector, rise in healthcare reforms, and technological advancements in cell therapy processing. The countries in this region are highly populated, with China being the first and India the second most populated countries. Therefore, the region possesses high growth potential owing to presence of huge patient base, which is expected to boost the growth of the Asia-Pacific cell therapy processing market. In addition, rise in demand for cell therapy processing, and presence of high population base incomes contribute toward the growth of the market. In addition, increase in research and development expenditure and surge in usage of cell therapy processing products augment the growth of the market. Furthermore, surge in focus of leading manufacturers on expanding their geographic presence in emerging Asia-Pacific countries to capture high market share is expected to drive the growth of the cell therapy processing market in the region.
The key players profiled in this report include Cell Therapies Pty Ltd, Invitrx Inc., Lonza Ltd, Merck & Co., Inc. (FloDesign Sonics), NantWorks, LLC, Neurogeneration, Inc., Novartis AG, Plasticell Ltd., Regeneus Ltd, and StemGenex, Inc.
By Geography
Asia-Pacific region would exhibit the highest CAGR of 29.0% during 2019-2026.
Key Benefits for Stakeholders:
- The study provides an in-depth analysis of the cell therapy processing market size along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers cell therapy processing market analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
- A comprehensive analysis of four regions is provided to determine the prevailing opportunities.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and global cell therapy processing market growth.
Cell Therapy Processing Market Report Highlights
| Aspects | Details |
 By Offering Type |
|
 By Application |
|
 By Region |
|
 Key Market Players | Merck & Co., Inc. (FloDesign Sonics), StemGenex, Inc., Novartis AG, Neurogeneration, Inc., LONZA LTD, Cell Therapies Pty Ltd, Plasticell Ltd., NantWorks, LLC, REGENEUS LTD, INVITRX INC. |
Analyst Review
Cell therapy processing includes the production of various cell therapy products such as cell lines, instrument, and software that help to improve the efficiency of cell therapies. The cell therapy processing used for the treatment of various diseases such as cardiovascular devices, bone repair, neurological disorders, skeletal muscle repair, cancer, and others.
Rise in prevalence of chronic diseases, surge in demand for chimeric antigen receptor (CAR) T cell therapy, rise in a number of clinical studies relating to the development of cell therapy processing, rise in the R&D for the advancement in the research associated with cell therapy, increase in adoption of regenerative medicine, introduction of novel technologies for cell therapy processing significantly boost the growth of the cell therapy processing market. Moreover, rise in patient awareness towards stem cell therapy, and increase in healthcare expenditure in the developed and developing regions fuel the growth of the global cell therapy processing market.
North America is expected to remain dominant during the forecast period, due to higher adoption of cell therapy processing technique with large presence of biotechnology companies, and R&D laboratories. In addition, presence of advanced facilities, and wide availability of advanced systems supplement the growth of the market. Moreover, Asia-Pacific and LAMEA are expected to offer lucrative opportunities to the key players during the forecast period, due to developments in infrastructure of biotechnology industries along with rise in demand for cell therapy processing technique.
The total market value of cell therapy processing market is $1,695.00 million in 2018.
The forcast period for cell therapy processing market is 2019 to 2026
The market value of cell therapy processing market in 2019 is $2,166.20 million.
The base year is 2018 in cell therapy processing market
Top companies such as,Cell Therapies Pty Ltd, Invitrx Therapeutics, Lonza Group Ltd., Merck & Co., Inc. (FloDesign Sonics), NantWorks, LLC, and Novartis AG held a high market position in 2018. These key players held a high market postion owing to the strong geographical foothold in different regions.
Software segment is the most influencing segment owing to surge in the prevalence of increase in the incidence of cardiovascular diseases. Furthermore, other factors that contribute to the growth of the market include rise in healthcare expenditure
The major factor that fuels the growth of the global cell therapy processing market includes increase in the incidence of cardiovascular diseases. This leads to surge in adoption of cell therapy processing systems for the treatment of these diseases, thereby fueling the growth of the global market
Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the following emerging countries such as India with a CAGR of 30.3%. This is due to Japan which serves as a hub for regenerative medicine research mainly driven by the support from Prime Minister Shinzo Abe.
Cell therapy is the administration of living cells to replace a missing cell type or to offer a continuous source of a necessary factor to achieve an effective therapeutic outcome. Various forms of cell therapies are available in the market, ranging from transplantation of cells derived from an individual patient or from another donor.
Cell therapy processing are employed therapy or treatment for treating various diseases such as cardiovascular diseases, bone repair, neurological disorders, skeletal muscle repair and others.
Loading Table Of Content...
